Low-dose DNA demethylating therapy induces reprogramming of diverse cancer-related pathways at the single-cell level
Open Access
- 21 September 2020
- journal article
- research article
- Published by Springer Nature in Clinical Epigenetics
- Vol. 12 (1) , 1-9
Abstract
Background: Epigenetic reprogramming using DNA demethylating drugs is a promising approach for cancer therapy, but its efficacy is highly dependent on the dosing regimen. Low-dose treatment for a prolonged period shows a remarkable therapeutic efficacy, despite its small demethylating effect. Here, we aimed to explore the mechanisms of how such low-dose treatment shows this remarkable efficacy by focusing on epigenetic reprograming at the single-cell level. Methods: Expression profiles in HCT116 cells treated with decitabine (DAC) were analyzed by single-cell RNA-sequencing (scRNA-seq). Functional consequences and DNA demethylation at the single-cell level were analyzed using cloned HCT116 cells after DAC treatment. Results: scRNA-seq revealed that DAC-treated cells had highly diverse expression profiles at the single-cell level, and tumor-suppressor genes, endogenous retroviruses, and interferon-stimulated genes were upregulated in random fractions of cells. DNA methylation analysis of cloned HCT116 cells revealed that, while only partial reduction of DNA methylation levels was observed in bulk cells, complete demethylation of specific cancer-related genes, such as cell cycle regulation, WNT pathway, p53 pathway, and TGF-β pathway, was observed, depending upon clones. Functionally, a clone with complete demethylation of CDKN2A (p16) had a larger fraction of cells with tetraploid than parental cells, indicating induction of cellular senescence due to normalization of cell cycle regulation. Conclusions: Epigenetic reprogramming of specific cancer-related pathways at the single-cell level is likely to underlie the remarkable efficacy of low-dose DNA demethylating therapy.Keywords
Funding Information
- The Foundation for Promotion of Cancer Research
- The Ministry of Health, Labour and Welfare (H22-002)
- The Japan Society for the Promotion of Science
- AMED (JP19ck0106421)
- the National Cancer Center Research and Development Fund (H26-A15, 29-E-7)
This publication has 36 references indexed in Scilit:
- A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancerInvestigational New Drugs, 2013
- Epigenetic Resensitization to Platinum in Ovarian CancerCancer Research, 2012
- Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor CellsCancer Cell, 2012
- Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non–Small Cell Lung CancerCancer Discovery, 2011
- A decade of exploring the cancer epigenome — biological and translational implicationsNature Reviews Cancer, 2011
- Cancer epigenomics: DNA methylomes and histone-modification mapsNature Reviews Genetics, 2007
- Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemiaBlood, 2006
- CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotypeCarcinogenesis, 2005
- Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignanciesBlood, 2004
- A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancerNature Genetics, 2002